{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T20:24:50Z","timestamp":1783110290759,"version":"3.54.6"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,5,14]],"date-time":"2019-05-14T00:00:00Z","timestamp":1557792000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,5,14]],"date-time":"2019-05-14T00:00:00Z","timestamp":1557792000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"name":"AstraZeneca Pharmaceuticals LP"},{"DOI":"10.13039\/100007658","name":"Baxter Healthcare Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007658","id-type":"DOI","asserted-by":"publisher"}]},{"name":"European Renal Association-European Dialysis & Transplant Association"},{"name":"Fresenius Medical Care Asia-Pacific Ltd"},{"name":"Fresenius Medical Care Canada Inc"},{"name":"German Society of Nephrology (DGfN), Italian Society of Nephrology"},{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Japanese Society for Peritoneal Dialysis"},{"name":"Keryx Biopharmaceuticals, Inc"},{"name":"Kidney Care UK"},{"DOI":"10.13039\/501100004095","name":"Kyowa Hakko Kirin","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004095","id-type":"DOI","asserted-by":"publisher"}]},{"name":"MEDICE Arzneimittel P\u00fctter GmbH & Co K"},{"DOI":"10.13039\/100009155","name":"Otsuka America Pharmaceutical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009155","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Proteon Therapeutics, Inc"},{"name":"The Association of German Nephrology Centres"},{"name":"Vifor Fresenius Medical Care Renal Pharma Ltd"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s12882-019-1355-5","type":"journal-article","created":{"date-parts":[[2019,5,14]],"date-time":"2019-05-14T15:04:43Z","timestamp":1557846283000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Predictors of cinacalcet discontinuation and reinitiation in hemodialysis patients: results from 7 European countries"],"prefix":"10.1186","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2448-5896","authenticated-orcid":false,"given":"Douglas S.","family":"Fuller","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Hallett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul J.","family":"Dluzniewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Fouqueray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Jadoul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hal","family":"Morgenstern","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Friedrich K.","family":"Port","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Tentori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald L.","family":"Pisoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,5,14]]},"reference":[{"key":"1355_CR1","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1038\/ki.2009.466","volume":"77","author":"H Komaba","year":"2010","unstructured":"Komaba H, Fukagawa M. FGF23\u2013parathyroid interaction: implications in chronic kidney disease. Kidney Int. 2010;77:292\u20138.","journal-title":"Kidney Int"},{"issue":"Suppl 1","key":"1355_CR2","doi-asserted-by":"publisher","first-page":"S35","DOI":"10.1111\/j.1744-9987.2005.00310.x","volume":"9","author":"J Cunningham","year":"2005","unstructured":"Cunningham J. Management of secondary hyperparathyroidism. Ther Apher Dial. 2005;9(Suppl 1):S35\u201340.","journal-title":"Ther Apher Dial"},{"key":"1355_CR3","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1038\/sj.ki.5002287","volume":"74","author":"WG Goodman","year":"2008","unstructured":"Goodman WG, Quarles LD. Development and progression of secondary hyperparathyroidism in chronic kidney disease: lessons from molecular genetics. Kidney Int. 2008;74:276\u201388.","journal-title":"Kidney Int"},{"key":"1355_CR4","doi-asserted-by":"publisher","first-page":"184321","DOI":"10.1155\/2015\/184321","volume":"2015","author":"E Hedgeman","year":"2015","unstructured":"Hedgeman E, Lipworth L, Lowe K, Saran R, Do T, Fryzek J. International burden of chronic kidney disease and secondary hyperparathyroidism: a systematic review of the literature and available data. Int J Nephrol. 2015;2015:184321.","journal-title":"Int J Nephrol"},{"key":"1355_CR5","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1093\/ndt\/gfn613","volume":"24","author":"A Covic","year":"2009","unstructured":"Covic A, Kothawala P, Bernal M, Robbins S, Chalian A, Goldsmith D. Systematic review of the evidence underlying the association between mineral metabolism disturbances and risk of all-cause mortality, cardiovascular mortality and cardiovascular events in chronic kidney disease. Nephrol Dial Transplant. 2009;24:1506\u201323.","journal-title":"Nephrol Dial Transplant"},{"key":"1355_CR6","doi-asserted-by":"publisher","first-page":"2208","DOI":"10.1097\/01.ASN.0000133041.27682.A2","volume":"15","author":"GA Block","year":"2004","unstructured":"Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol. 2004;15:2208\u201318.","journal-title":"J Am Soc Nephrol"},{"key":"1355_CR7","doi-asserted-by":"publisher","first-page":"98","DOI":"10.2215\/CJN.12941213","volume":"10","author":"F Tentori","year":"2015","unstructured":"Tentori F, Wang M, Bieber BA, Karaboyas A, Li Y, Jacobson SH, et al. Recent changes in therapeutic approaches and association with outcomes among patients with secondary hyperparathyroidism on chronic hemodialysis: the DOPPS study. Clin J Am Soc Nephrol. 2015;10:98\u2013109.","journal-title":"Clin J Am Soc Nephrol"},{"key":"1355_CR8","doi-asserted-by":"publisher","first-page":"913","DOI":"10.2215\/CJN.06040710","volume":"6","author":"J Cunningham","year":"2011","unstructured":"Cunningham J, Locatelli F, Rodriguez M. Secondary hyperparathyroidism: pathogenesis, disease progression, and therapeutic options. Clin J Am Soc Nephrol. 2011;6:913\u201321.","journal-title":"Clin J Am Soc Nephrol"},{"key":"1355_CR9","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1002\/pds.3845","volume":"24","author":"SM Brunelli","year":"2015","unstructured":"Brunelli SM, Dluzniewski PJ, Cooper K, Do TP, Sibbel S, Bradbury BD. Management of serum calcium reductions among patients on hemodialysis following cinacalcet initiation. Pharmacoepidemiol Drug Saf. 2015;24:1058\u201367.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"1355_CR10","unstructured":"European Medicines Agency. Mimpara (cinacalcet hydrochloride) prescribing information. Available at http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000570\/WC500028900.pdf . Accessed 15 Feb 2018."},{"key":"1355_CR11","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1111\/hdi.12503","volume":"21","author":"B Bikbov","year":"2017","unstructured":"Bikbov B, Bieber B, Andrusev A, Tomilina N, Zemchenkov A, Zhao J, et al. Hemodialysis practice patterns in the Russia Dialysis Outcomes and Practice Patterns Study (DOPPS), with international comparisons. Hemodial Int. 2017;21:393\u2013408.","journal-title":"Hemodial Int"},{"key":"1355_CR12","doi-asserted-by":"publisher","first-page":"1516","DOI":"10.1056\/NEJMoa031633","volume":"350","author":"GA Block","year":"2004","unstructured":"Block GA, Martin KJ, de Francisco AL, Turner SA, Avram MM, Suranyi MG, et al. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med. 2004;350:1516\u201325.","journal-title":"N Engl J Med"},{"key":"1355_CR13","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1681\/ASN.2004060512","volume":"16","author":"JS Lindberg","year":"2005","unstructured":"Lindberg JS, Culleton B, Wong G, Borah MF, Clark RV, Shapiro WB, et al. Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: a randomized, double-blind, multicenter study. J Am Soc Nephrol. 2005;16:800\u20137.","journal-title":"J Am Soc Nephrol"},{"key":"1355_CR14","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1097\/EDE.0000000000000766","volume":"29","author":"MA Brookhart","year":"2018","unstructured":"Brookhart MA, Reams D, Dluzniewski PJ, Kshirsagar A, Walsh L, Bradbury BD. Estimating the effect of preventable treatment discontinuation on health outcomes. Epidemiology. 2018;29:134\u201341.","journal-title":"Epidemiology"},{"key":"1355_CR15","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1046\/j.1523-1755.2003.00064.x","volume":"64","author":"R Saran","year":"2003","unstructured":"Saran R, Bragg-Gresham JL, Rayner HC, Goodkin DA, Keen ML, Van Dijk PC, et al. Nonadherence in hemodialysis: associations with mortality, hospitalization, and practice patterns in the DOPPS. Kidney Int. 2003;64:254\u201362.","journal-title":"Kidney Int"},{"key":"1355_CR16","doi-asserted-by":"crossref","first-page":"222","DOI":"10.4037\/ajcc2007.16.3.222","volume":"16","author":"K Denhaerynck","year":"2007","unstructured":"Denhaerynck K, Manhaeve D, Dobbels F, Garzoni D, Nolte C, De Geest S. Prevalence and consequences of nonadherence to hemodialysis regimens. Am J Crit Care. 2007;16:222\u201335.","journal-title":"Am J Crit Care"},{"key":"1355_CR17","doi-asserted-by":"publisher","first-page":"798","DOI":"10.3111\/13696998.2011.627404","volume":"14","author":"A Lee","year":"2011","unstructured":"Lee A, Song X, Khan I, Belozeroff V, Goodman W, Fulcher N, et al. Association of cinacalcet adherence and costs in patients on dialysis. J Med Econ. 2011;14:798\u2013804.","journal-title":"J Med Econ"},{"key":"1355_CR18","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1111\/j.1524-4733.2007.00213.x","volume":"11","author":"JA Cramer","year":"2008","unstructured":"Cramer JA, Roy A, Burrell A, Fairchild CJ, Fuldeore MJ, Ollendorf DA, et al. Medication compliance and persistence: terminology and definitions. Value Health. 2008;11:44\u20137.","journal-title":"Value Health"},{"key":"1355_CR19","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1186\/2047-783X-14-5-185","volume":"14","author":"H Schmid","year":"2009","unstructured":"Schmid H, Hartmann B, Schiffl H. Adherence to prescribed oral medication in adult patients undergoing chronic hemodialysis: a critical review of the literature. Eur J Med Res. 2009;14:185\u201390.","journal-title":"Eur J Med Res"},{"key":"1355_CR20","doi-asserted-by":"publisher","first-page":"e0144119","DOI":"10.1371\/journal.pone.0144119","volume":"10","author":"S Ghimire","year":"2015","unstructured":"Ghimire S, Castelino RL, Lioufas NM, Peterson GM, Zaidi ST. Nonadherence to medication therapy in haemodialysis patients: a systematic review. PLoS One. 2015;10:e0144119.","journal-title":"PLoS One"},{"key":"1355_CR21","first-page":"862","volume":"20","author":"H Park","year":"2014","unstructured":"Park H, Rascati KL, Lawson KA, Barner JC, Richards KM, Malone DC. Adherence and persistence to prescribed medication therapy among Medicare part D beneficiaries on dialysis: comparisons of benefit type and benefit phase. J Manag Care Spec Pharm. 2014;20:862\u201376.","journal-title":"J Manag Care Spec Pharm"},{"key":"1355_CR22","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1159\/000350213","volume":"37","author":"RD Kilpatrick","year":"2013","unstructured":"Kilpatrick RD, Newsome BB, Zaun D, Liu J, Solid CA, Nieman K, et al. Evaluating real-world use of cinacalcet and biochemical response to therapy in U.S. hemodialysis patients. Am J Nephrol. 2013;37:389\u201398.","journal-title":"Am J Nephrol"},{"key":"1355_CR23","doi-asserted-by":"publisher","first-page":"2852","DOI":"10.1093\/ndt\/gfp144","volume":"24","author":"P Ure\u00f1a","year":"2009","unstructured":"Ure\u00f1a P, Jacobson SH, Zitt E, Vervloet M, Malberti F, Ashman N, et al. Cinacalcet and achievement of the NKF\/K-DOQI recommended target values for bone and mineral metabolism in real-world clinical practice--the ECHO observational study. Nephrol Dial Transplant. 2009;24:2852\u20139.","journal-title":"Nephrol Dial Transplant"},{"key":"1355_CR24","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1186\/s12882-015-0174-6","volume":"16","author":"BD Reams","year":"2015","unstructured":"Reams BD, Dluzniewski PJ, Do TP, Yue SV, Bradbury BD, Kshirsagar AV, et al. Dynamics of cinacalcet use and biochemical control in hemodialysis patients: a retrospective new-user cohort design. BMC Nephrol. 2015;16:175.","journal-title":"BMC Nephrol"},{"key":"1355_CR25","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.nefro.2015.10.006","volume":"36","author":"AL de Francisco","year":"2016","unstructured":"de Francisco AL, Gillespie IA, Gioni I, Floege J, Kronenberg F, Marcelli D, et al. Anti-parathyroid treatment effectiveness and persistence in incident haemodialysis patients with secondary hyperparathyroidism. Nefrologia. 2016;36:164\u201375.","journal-title":"Nefrologia"},{"key":"1355_CR26","first-page":"S1","volume":"113","author":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group","year":"2009","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl. 2009;113:S1\u2013130.","journal-title":"Kidney Int Suppl"},{"key":"1355_CR27","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1016\/j.kint.2017.12.014","volume":"93","author":"J Floege","year":"2018","unstructured":"Floege J, Tsirtsonis K, Iles J, Drueke TB, Chertow GM, Parfrey P. Incidence, predictors and therapeutic consequences of hypocalcemia in patients treated with cinacalcet in the EVOLVE trial. Kidney Int. 2018;93:1475\u201382.","journal-title":"Kidney Int"},{"key":"1355_CR28","doi-asserted-by":"publisher","first-page":"104892","DOI":"10.1155\/2013\/104892","volume":"2013","author":"V Forni Ogna","year":"2013","unstructured":"Forni Ogna V, Pruijm M, Zweiacker C, Wuerzner G, Tousset E, Burnier M. Clinical benefits of an adherence monitoring program in the management of secondary hyperparathyroidism with cinacalcet: results of a prospective randomized controlled study. Biomed Res Int. 2013;2013:104892.","journal-title":"Biomed Res Int"},{"key":"1355_CR29","doi-asserted-by":"publisher","first-page":"199","DOI":"10.5414\/CNP72199","volume":"72","author":"M Pruijm","year":"2009","unstructured":"Pruijm M, Teta D, Halabi G, Wuerzner G, Santschi V, Burnier M. Improvement in secondary hyperparathyroidism due to drug adherence monitoring in dialysis patients. Clin Nephrol. 2009;72:199\u2013205.","journal-title":"Clin Nephrol"},{"key":"1355_CR30","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1001\/jama.2016.19468","volume":"317","author":"GA Block","year":"2017","unstructured":"Block GA, Bushinsky DA, Cheng S, Cunningham J, Dehmel B, Drueke TB, et al. Effect of etelcalcetide vs cinacalcet on serum parathyroid hormone in patients receiving hemodialysis with secondary hyperparathyroidism: a randomized clinical trial. JAMA. 2017;317:156\u201364.","journal-title":"JAMA"},{"key":"1355_CR31","doi-asserted-by":"publisher","first-page":"69","DOI":"10.2147\/IJNRD.S128252","volume":"11","author":"KE Eidman","year":"2018","unstructured":"Eidman KE, Wetmore JB. Managing hyperparathyroidism in hemodialysis: role of etelcalcetide. Int J Nephrol Renov Dis. 2018;11:69\u201380.","journal-title":"Int J Nephrol Renov Dis"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-019-1355-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12882-019-1355-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-019-1355-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,12]],"date-time":"2020-12-12T20:17:09Z","timestamp":1607804229000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcnephrol.biomedcentral.com\/articles\/10.1186\/s12882-019-1355-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,14]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["1355"],"URL":"https:\/\/doi.org\/10.1186\/s12882-019-1355-5","relation":{},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,14]]},"assertion":[{"value":"22 August 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"DOPPS was approved by a central institutional review board (IRB) in the US, Ethical and Independent Review Services, with additional IRB study approval and written patient consent obtained to meet national and local ethics committee regulations at each study site.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"PJD and BF are employees and stockholders of Amgen, Inc.; DH is a contingent worker hired by Amgen, Inc. and an employee of Simulstat, Inc.; MJ has received research grants from, and is a member of the speaker\u2019s bureau for, Amgen, Inc.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"169"}}